Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-2: SOF/VEL/VOX vs SOF/VEL in DAA-Naive HCV
NCT02607800Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of voxilaprevir in hepatitis C (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event up to 12 weeks. Started Nov 2015; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02607800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607800.